Bull
$186.19
シナリオ価格
$120.250
+4.052 (+3.37%)終値時点
iRhythm Holdings, Inc. is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. The Company's principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. The Company provides Zio ambulatory cardiac monitoring services, including long-term continuous monitoring (LTCM), short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using a proprietary system that combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor that continuously records ECG data, with a proprietary FDA-cleared, CE-marked, Japan PDMA approved cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
iRhythm Technologies Inc is a good buy right now due to its recent strong Q2 results, which showed sales of $224.17 million and a narrowed net loss of only $0.381 million. Additionally, the company raised its full-year revenue guidance to $880 million–$890 million, reflecting an expected growth of 18%-19% year-over-year. However, the stock has a high forward P/E ratio of 500, indicating that it may be overvalued if growth does not meet expectations.
Truist
$168
2026-08-10
Truist
2026-08-10
目標株価
$168
Canaccord
$196
2026-08-07
Canaccord
2026-08-07
目標株価
$196
Baird
$165
2026-08-07
Baird
2026-08-07
目標株価
$165
Stephens
$160
2026-07-22
Stephens
2026-07-22
目標株価
$160
Truist
$160
2026-07-16
Truist
2026-07-16
目標株価
$160
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Three Small-Cap Stocks for Long-Term Investors

Investigation into iRhythm Shareholder Rights

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties

iRhythm Executives Allegedly Breached Fiduciary Duties to Shareholders
iRhythm Holdings, Inc. is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. The Company's principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. The Company provides Zio ambulatory cardiac monitoring services, including long-term continuous monitoring (LTCM), short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using a proprietary system that combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor that continuously records ECG data, with a proprietary FDA-cleared, CE-marked, Japan PDMA approved cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
iRhythm Technologies Inc is a good buy right now due to its recent strong Q2 results, which showed sales of $224.17 million and a narrowed net loss of only $0.381 million. Additionally, the company raised its full-year revenue guidance to $880 million–$890 million, reflecting an expected growth of 18%-19% year-over-year. However, the stock has a high forward P/E ratio of 500, indicating that it may be overvalued if growth does not meet expectations.
4 analysts cover IRTC: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 222.00.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。